
    
      This is a two-part, double-blind, randomized, placebo-controlled, and open-label Phase III
      study to investigate the efficacy, safety of Hetrombopag in pediatric patients with
      previously treated chronic ITP. In Part A, patients will receive Hetrombopag for 8 weeks.
      After completing Part A, patients will begin Part B, in which they will be randomized to
      receive Hetrombopag or placebo in a 12 week double-blind, placebo-controlled treatment
      period, following an open-label 12 week treatment period.
    
  